head and neck squamous cell carcinoma
Conditions
Interventions
cohort 1:paclitaxel combined with cisplatin plus an Anlotinib
cohort2:paclitaxel combined with cisplatin
Sponsors
Daping Hospital, Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 255 patients with head and neck squamous cell carcinoma diagnosed in the army characteristic medical center of the Army Medical University from May 2018 to June 2020 were included.
Exclusion criteria
Exclusion criteria: 1. Pregnancy or breast feeding; 2. Patients with hypertension and antihypertensive medication can not be reduced to normal range (systolic blood pressure > 150 mmHg, diastolic blood pressure > 100 mmHg); 3. Patients with grade II or higher myocardial infarction, arrhythmia, grade III~IV cardiac function or cardiac ejection fraction 1.5 or PT > ULN+4s or APTT > 1.5 ULN), with bleeding tendency, or receiving thrombolytic or anticoagulant therapy; 5. Urine protein positive patients; 6. Accompanied by serious uncontrollable infection or medical diseases; 7. A person who has been confirmed to be allergic to Anlotinib and/or its excipients; 8. Patients with central nervous system metastases; 9. Patients with a history of psychotropic substance abuse who are unable to quit or have a mental disorder; 10. With severe heart, lung, liver, kidney and other important organ dysfunction;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Countries
China
Contacts
Public ContactZhao-Yang Zhong
Daping Hospital, Army Medical University
Outcome results
None listed